ProQR Therapeutics, a company focused on treating rare diseases, announced plans to advance its pipeline of RNA medicines to treat inherited retinal diseases to include two fully approved commercial products in Europe and the U.S., three late-stage clinical therapies and seven early-stage therapies by 2023.
The company, founded in 2012, is developing a platform of RNA medicines to correct genetic defects in the patient’s RNA without having to modify DNA, ProQR CEO Daniel A. de Boer told Ocular Surgery News.
“This allows us to target a wide variety of diseases. (Read more...)
Uncategorized